Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Structure TherapeuticsGPCR +1.32%32 Debt-to-EBITDA is -0.02 as of Mar. 2026. GuruFocus rates GPCR with a GF Score™ of 32/100. Among 291 Biotechnology companies, Structure Therapeutics ranks worse than 343642.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Structure Therapeutics's Debt-to-EBITDA or its related term are showing as below:
GPCR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.05 Med: -0.02 Max: -0.01
Current: -0.03
During the past 6 years, the highest Debt-to-EBITDA Ratio of Structure Therapeutics was -0.01. The lowest was -0.05. And the median was -0.02.
GPCR's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs GPCR: -0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Structure Therapeutics Debt-to-EBITDA Related Terms
Structure Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Structure Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GPCR vs PBLS, IDYA, ELVN: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Structure Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Structure Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Structure Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Structure Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Structure Therapeutics (GPCR) has a Debt-to-EBITDA of -0.02 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Structure Therapeutics. According to the industry distribution chart, Structure Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry.
Is Structure Therapeutics' Debt-to-EBITDA too high?
Structure Therapeutics' current Debt-to-EBITDA is -0.02. Based on the distribution chart, Structure Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' Debt-to-EBITDA compare to PBLS and IDYA?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Structure Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Structure Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Structure Therapeutics's current Debt-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current Debt-to-EBITDA of -0.02. The current Debt-to-EBITDA is -0.02. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current Debt-to-EBITDA is -0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score
Get the complete analysis for GPCR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GPCR has been successfully added to your 
